The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Small Molecule Therapeutics: From Infectious And Parasitic Diseases To Cancers
Funder
National Health and Medical Research Council
Funding Amount
$763,845.00
Summary
I will lead a team of medicinal chemists to discover better treatments of diseases focused in two major domains. On one hand, I will discover new drugs to treat certain parasitic diseases such as Sleeping Sickness, Chagas disease and malaria, all caused by protozoal parasites. On the other hand, I will discover new drugs to treat certain cancers, in particular acute myeloid leukemia and Burkitt’s lymphoma, caused by dysfunction of certain types of enzymes called histone acetyltransferases.
Biomedical Investigations Of Pharmacology And Pathology For Disease Treatment
Funder
National Health and Medical Research Council
Funding Amount
$863,413.00
Summary
I am an NHMRC SPRF & Director of the Molecular Pharmacology & Pathology Program consisting of 34 researchers. The breadth of our studies is diverse & continues to expand. Excitingly, we have recently obtained commercialisation support to develop our anti-tumour drug, DpC. My vision for the next 5 yrs is to direct development of these agents together with investigations of basic mechanism. These studies will be done with a team of outstanding researchers I am mentoring and an established group of ....I am an NHMRC SPRF & Director of the Molecular Pharmacology & Pathology Program consisting of 34 researchers. The breadth of our studies is diverse & continues to expand. Excitingly, we have recently obtained commercialisation support to develop our anti-tumour drug, DpC. My vision for the next 5 yrs is to direct development of these agents together with investigations of basic mechanism. These studies will be done with a team of outstanding researchers I am mentoring and an established group of experienced collaborators.Read moreRead less
Prof A Suhrbier is the Group Leader of the Inflammation Biology Group at the Queensland Institute of Medical Research. The group focuses at the applied end of inflammation research and development and will be involved in the identification and development of new interventions and diagnostics for inflammatory diseases and cancer, often in collaboration with the biotech industry.
Translational Research Initiatives In Acute Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$631,010.00
Summary
Recent research has focussed on molecular characterisation of high-risk acute leukaemia subtypes. This proposal will combine the power of genomic analysis, global analysis of protein kinases and stringent preclinical drug testing in order to improve the treatment of these high-risk acute leukaemia subtypes. Several innovative and interrelated projects within this Program will utilise a unique and clinically relevant experimental model to achieve their goals.
Venoms To Drugs: Translating Venom Peptides Into Human Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$774,540.00
Summary
Many disorders of the nervous system, including chronic pain, epilepsy and the neuronal degeneration suffered following a stroke, result from malfunction of channels that ferry ions across neuronal cell membranes. There are very few drugs available for treating these disorders and they often have debilitating side-effects. We are developing potent and selective modulators of these ion channels as the next-generation of safe and effective analgesic, anti-epileptic, and neuroprotective drugs.
We will investigate malaria, a parasitic disease that kills over 600,000 people a year. We will explore how the parasite identifies, invades and remodels the host cells in which it lives, scavenging nutrients and hiding from the immune system. We will characterize the proteins involved in these critical events, as they are potential targets for drugs and vaccines. We will study how parasites cause disease and how the host responds to infection.
Next Generation Relaxin Molecular Probes And Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$763,845.00
Summary
The peptide hormone relaxin is poised to be the first new treatment for acute heart failure in more than 40 years. However, like other therapeutic peptides, it has a very short duration of action due to its rapid clearance by the body. My work will utilize powerful medicinal chemistry methods to develop new analogues of relaxin that have much longer action by complexing it with sugar or making relaxin polymers. I will also produce smaller relaxin analogues that will be cheaper to manufacture.
Towards A Better Understanding Of The Health Benefits Of Physical Activity: Designing Exercise Mimetic For The Treatment Of Disease
Funder
National Health and Medical Research Council
Funding Amount
$938,910.00
Summary
The health benefits of physical activity are well known but the mechanisms linking regular physical activity to chronic disease prevention are poorly understood. We have developed the concept that contracting muscles release factors that have positive effects on other organs in the body. This fellowship will allow me to develop this concept and uncover novel potential therapies that mimic the benefits of exercise.
Ion channels are molecular pores of excitable membranes facilitating passage of ions and organic solutes across cellular membranes. An ever-increasing number of human and animal diseases result from malfunctioning ion channels making them to important therapeutic targets, which are modulated by a range of currently prescribed drugs. In the recent years the scientific and medical community has become increasingly aware of the role that mechanosensitive ion channels play in pathology of diseases i ....Ion channels are molecular pores of excitable membranes facilitating passage of ions and organic solutes across cellular membranes. An ever-increasing number of human and animal diseases result from malfunctioning ion channels making them to important therapeutic targets, which are modulated by a range of currently prescribed drugs. In the recent years the scientific and medical community has become increasingly aware of the role that mechanosensitive ion channels play in pathology of diseases including cardiac hyperthrophy and arrhythmias.Read moreRead less
The key goal of my research is to understand the role of protein phosphorylation in controlling metabolism, with a special emphasis on the structure and function of members of the AMP-activated protein kinase (AMPK) pathway. This is important because the function and survival of all organisms is dependent on the dynamic control of energy metabolism, with energy demand matched to energy supply.